Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc.
Your view on MLYS
Overview
What the company does, where it operates, and who runs it.
About Mineralys Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jon Congleton
- Headquarters
- 150 N. Radnor Chester Rd., Radnor, PA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jon Congleton
- Headquarters
- 150 N. Radnor Chester Rd., Radnor, PA, US
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.